Study of AMG531(Romiplostim) in Patients With Aplastic Anemia

Study Overview
=================
Brief Summary
-----------------
To evaluate the hematological responses based on the response assessment criteria when AMG531 is subcutaneous (SC)-administered with anti-human thymocyte immunoglobulin (ATG) + ciclosporin A (CsA) therapy for 6 months in patients with aplastic anemia (AA) who were previously untreated with immunosuppressive therapy.

Official Title
-----------------
A Phase 2/3 Study of AMG531 in Patients With Aplastic Anemia PreviouslyUntreated With Immunosuppressive Therapy

Conditions
-----------------
Aplastic Anemia

Intervention / Treatment
-----------------
* Drug: Romiplostim


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Voluntary signed informed consent to participate in the study; A diagnosis of AA confirmed by blood and bone-marrow examinations, etc.; Considered to require new treatment with ATG and CsA provided that NSAA must be platelet or erythrocyte transfusion-dependent. An Eastern Cooperative Oncology Group (ECOG) performance status (PS) score of 0 to 1at screening Exclusion Criteria: Previously treated with ATG, CsA, or Alemtuzumab; Diagnosed as having congenital AA (Fanconi anemia, congenital dyskeratosis, etc.); Diagnosed as having AML or chronic myelomonocytic leukemia; Concurrent thrombocytopenia of other etiologies (e.g., MDS, ITP, cirrhosis); Concurrent active infection not adequately responding to appropriate therapy; Concurrent clinically significant illness(es) items which are deemed by the Investigator to be likely to affect the study conduct and assessments. Having active malignancies, or having a history of treatment of malignancies within 5 years prior to informed consent. Concurrent PNH Having Grade 2 or higher bone marrow reticulin based on Bone Marrow Pathology (2nd edition) ; History of chromosome aberrations discovered in bone marrow cells. Having blast cells > 2% in bone marrow; Positive for anti-human immunodeficiency virus (HIV) antibody; Receiving prophylactic or therapeutic treatment for hepatitis type B Positive for hepatitis C virus (HCV) antibody, and HCV infection being confirmed Planned hematopoietic stem cell transplantation during the study; Systemic treatment with any of the following medication for the treatment of AA within 4 weeks before Day 1, however, excluding their use as premedication: Anabolic steroids Corticosteroids; Pregnant or breastfeeding women, or women willing to become pregnant; Other conditions unsuitable for participation in the study in the opinion of the Investigator.

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Interventional Model Description: multi-national, open-label, phase 2/3 study
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: AMG531<br> | Drug: Romiplostim<br>* Romiplostim SC. Initial dose is 10 ug/kg/. Maximum dose is 20 ug/kg. Original duration is 6 months from first administration but if investigator decide that the patient is needed more treatment, they move to extention period and take treatment up to 1 year.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Achievement of complete response (CR) or partial response (PR) |  | 27 weeks post-dose | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Achievement of CR or PR |  | Week 14 | 
| Achievement of CR |  | Weeks 14 and 27 | 
| The time to CR or PR |  | Each time point evaluated weekly until Week 27 | 
| Reduction or independence of platelet and/or erythrocyte transfusion |  | Week 27 | 
| Change from baseline in platelet count (/µL) |  | Each time point evaluated weekly until Week 27 | 
| Change from baseline in hemoglobin (Hb) concentration (g/dL) |  | Each time point evaluated weekly until Week 27 | 
| Change from baseline in neutrophil count (/µL) |  | Each time point evaluated weekly until Week 27 | 
| Change from baseline in reticulocyte count (/µL) |  | Each time point evaluated weekly until Week 27 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
aplastic anemia, romiplostim